NCT06080035

The Effects of Cetyl Tranexamate Mesylate on the Appearance of Acne-Related Hyperpigmentation

Open-label, Prospective Study on the Effects of Cetyl Tranexamate Mesylate on the Appearance of Acne-Related Hyperpigmentation

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Integrative Skin Science and Research · Industry
• Sex: All
• Age: 14 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the effects of Cetyl Tranexamate Mesylate on acne-related hyperpigmentation through a specific delivery form known as TeraCeutic TXVector.

Detailed description

Hyperpigmentation is characterized as an increase in pigment on the skin and is a common skin condition in individuals with skin types III to VI on the Fitzpatrick skin classification scale. Hyperpigmentation can be localized to an area in the form of post-inflammatory hyperpigmentation or diffused in the form of melasma. One of the treatments that are used to treat hyperpigmentation is tranexamic acid (TXA) which is a third-generation bioactive and is formally known to work as a plasmin inhibitor. Since TXA is hydrophilic in nature and has a strong hydrogen-bonding capacity, it has an insufficient skin permeability. Similar to TXA esters, Cetyl Tranexamate Mesylate (CTM) is hypothesized to have greater permeability and this study will evaluate the effects of CTM on the appearance of post-inflammatory hyperpigmentation.

Conditions

• Hyperpigmentation
• Post-inflammatory Hyperpigmentation
• Acne

Interventions

Type	Name	Description
OTHER	Topical Cetyl Tranexamate Mesylate	Topical product will be applied onto clean skin morning and night.

Timeline

• Start date: 2023-11-06
• Primary completion: 2024-01-11
• Completion: 2024-01-11
• First posted: 2023-10-12
• Last updated: 2024-08-28

Locations

1 site across 1 country: United States